|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
BioDelivery Sciences International, Inc., Newark
| | | Phone: | (973) 972-1045 | Fax: | (973) 972-0323 | Year Established: | 1998 | Ticker: | BDSI | Exchange: | NASDAQ | Main Contact: | Al Medwar, Senior VP, Corporate & Business Development | | Other Contacts: | Enoch Bortey, Ph.D., VP, Clinical Biostatistics & Data Systems J. Chris Prue, RPh, MBA, VP, RA & QA James A. McNulty, CPA, Senior VP, Finance & Treasurer Niraj Vasisht, Ph.D., Senior VP & CTO Steven Dykstra, Senior VP, Manufacturing Operations Ernest R. De Paolantonio, CPA MBA, CFO Andrew L. Finn, Pharm.D., Executive VP, Product Development Sarah DeRossett, MD, PhD, VP, Clinical Research & Medical Affairs Raphael J. Mannino, Ph.D., Executive VP & CSO Mark A. Sirgo, Pharm. D., President & CEO
| | Company Description | BioDelivery Sciences is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence. BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Pharmaceuticals. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron). | |
|
|
|